Browsing Tag
Alembic Pharmaceuticals
21 posts
Can an FDA approval move the needle for Alembic Pharmaceuticals stock?
Alembic Pharmaceuticals gains USFDA approval for a key injectable in the U.S. Find out how this regulatory win influences its stock, valuations, and pipeline story.
Can Jagsonpal Pharmaceuticals’ dermatology push turn into a breakout growth segment?
Jagsonpal Pharmaceuticals is expanding its dermatology portfolio, aiming to turn anti-fungal and skin-care therapies into its next big growth driver in India.
Alembic Pharmaceuticals secures final approval from FDA for hypertension drug
Alembic Pharmaceuticals Limited has successfully secured final approval from the US Food and Drug Administration (USFDA) for its…
Alembic Pharmaceuticals wins big with FDA approval for new allergy eye drops
In a major development that could impact the over-the-counter pharmaceutical market, Alembic Pharmaceuticals Limited has received final approval…
Alembic Pharmaceuticals secures USFDA approval for new Paliperidone extended-release tablets
Alembic Pharmaceuticals Limited has achieved a major milestone in the pharmaceutical industry. On September 27, 2024, the company…
Tentative approval granted to Alembic Pharmaceuticals for pulmonary hypertension treatment by FDA
Alembic Pharmaceuticals Limited has achieved a significant milestone by securing tentative approval from the US Food & Drug…
Alembic Pharmaceuticals gains FDA approval for Icatibant Injection
Alembic Pharmaceuticals Limited has achieved a significant milestone with the US Food & Drug Administration’s (USFDA) final approval…
Alembic Pharmaceuticals gets FDA final approval for Desonide Cream, 0.05%
Alembic Pharmaceuticals has secured final approval for its abbreviated new drug application (ANDA) of Desonide Cream, 0.05% from…
Alembic Pharmaceuticals secures US FDA approval for Ketorolac Tromethamine injectable as generic to Roche’s Toradol
Alembic Pharmaceuticals wins US FDA approval for Ketorolac Tromethamine injectable, a generic to Roche’s Toradol, expanding its US sterile injectables portfolio.
Alembic Pharmaceuticals secures FDA final approval for generic mesalamine extended-release capsules for ulcerative colitis remission
Alembic Pharmaceuticals gains US FDA approval for its generic mesalamine extended-release capsules, targeting the $133M ulcerative colitis market.